MarginsXMarginsX
Home › Markets › Health Care › PHAR

Pharming Group N.V. ADS each representing 10 (PHAR)

PHAR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$12.59
-0.08% on the day
Market cap
$889.2M
Small cap
Revenue · 2025
$376.1M
+26.6% on 2024
Net income · 2025
$2.9M
0.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/0001828316-26-000015-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPHAR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNetherlands
IPO yearNot reported by the screener
SEC CIK0001828316
SEC industry codePharmaceutical Preparations
Incorporated inNetherlands

Financials · 2025

LineValue
Revenue$376.1M
Net income$2.9M
Operating income$25.8M
Net margin0.8%
Operating margin6.9%
Revenue growth+26.6%
Cash$145.3M
Total assets$500.0M
P/E (computed)311.9×
P/S (computed)2.4×

Warning signs

Cash runway
Cash-flow positive
$145.3M cash at December 31, 2025
Share count, 1 year
+3.1%
2024-12-31 to 2025-12-31 · +6.9% over 3 years
Going-concern doubt
No
20-F filed April 2, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-02
Cash and burn$145.3M cash; operating cash flow $13.7M a quarter.Report 2025-12-31
Shares outstanding70,168,044 (2025-12-31); 68,030,874 a year earlier; 65,634,823 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte Accountants B.V., Eindhoven, NetherlandsPCAOB Form AP 2026-04-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$376.1M$2.9M$54.7M$145.3MNo debt tags$376.1M20-F 2026-04-02
FY 2024
2024-12-31
$297.2M-$11.8M-$1.8M$54.9MNo debt tags$297.2M20-F 2026-04-02
FY 2023
2023-12-31
$245.3M-$10.5M-$17.3M$61.7MNo debt tags$245.3M20-F 2026-04-02
FY 2022
2022-12-31
$205.6M$13.7M$22.5M$207.3MNo debt tags$205.6M20-F 2025-04-03
FY 2021
2021-12-31
$198.9M$16.0M$37.8M$191.9MNo debt tags$198.9M20-F 2024-04-04
FY 2020
2020-12-31
$212.2M$37.7M$83.6M$205.2MNo debt tags$212.2M20-F 2023-04-05
FY 2019
2019-12-31
$189.4M$40.6M$74.1M$74.3MNo debt tags$189.4M20-F 2022-04-06

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42020-12-23
Latest annual report20-F2026-04-02
Latest quarterly / interim6-K2026-11-06

Source: SEC EDGAR submissions feed, 149 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.5%
1 month+33.5%
3 months+2.0%
Year to date-28.7%
1 year-28.5%
From 52-week high-40.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CRVSCorvus Pharmaceuticals Inc.$10.60-0.38%$894.1M
AKTSAktis Oncology Inc.$16.16-2.77%$901.7M
CTYCity Therapeutics Inc.$16.98-6.19%$854.6M
LTGOLatigo Biotherapeutics Inc.$12.60-3.89%$835.4M
RIGLRigel Pharmaceuticals Inc.$43.73-1.64%$823.4M
SNDXSyndax Pharmaceuticals Inc.$9.13-3.39%$821.6M
VSTMVerastem Inc.$7.70-5.87%$970.3M
JBIOJade Biosciences Inc.$15.34-4.99%$975.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier